Royalty Pharma plc
RPRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001802768
In the last 90 days, Royalty Pharma plc insiders filed 0 open-market purchases and 4 sales; 650 institutions reported holding it in 13F filings for Q2 2026, worth $20.6B in total; Dorsey Asset Management is the only superinvestor holding it.
13F holders, Q4 2022
Institutional positions in Royalty Pharma plc as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 338
- +26 vs. Q3 2022
- Shares held
- 299.5M
- +2.50M (+0.8%) vs. Q3 2022
- Total value
- $11.8B
- −$106.0M (−0.9%) vs. Q3 2022
- New holders
- 61
- 139 more added
- Sold out
- 35
- 100 more reduced
8 institutions that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting RPRX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 650 | $20.6B |
| Q1 2026 | 594 | $17.0B |
| Q4 2025 | 542 | $13.8B |
| Q3 2025 | 490 | $11.6B |
| Q2 2025 | 458 | $12.4B |
| Q1 2025 | 447 | $9.67B |
| Q4 2024 | 417 | $8.21B |
| Q3 2024 | 396 | $8.85B |
| Q2 2024 | 380 | $8.36B |
| Q1 2024 | 381 | $9.49B |
| Q4 2023 | 364 | $8.74B |
| Q3 2023 | 315 | $8.17B |
| Q2 2023 | 327 | $9.33B |
| Q1 2023 | 338 | $10.9B |
| Q4 2022 | 338 | $11.8B |
| Q3 2022 | 320 | $12.0B |
| Q2 2022 | 286 | $12.3B |
| Q1 2022 | 280 | $10.5B |
| Q4 2021 | 267 | $10.7B |
| Q3 2021 | 234 | $9.59B |
| Q2 2021 | 238 | $10.3B |
| Q1 2021 | 216 | $10.7B |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding Royalty Pharma plc; share changes are against Q3 2022.